Orionis Biosciences

Foundation date

01/09/2015

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

We are an early stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical need – with an initial internal focus in oncology and immunotherapies.

Upcoming events

Latest news

  • V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

    Wednesday April 24th 2024

  • Labconsort and NEKTARI join forces for a more sustainable and social industry

    Saturday April 20th 2024

  • BIO INX Complements Advisory Board with Distinguished Industry Leaders

    Thursday April 18th 2024